Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of Tuesday, October 6, 2026.
RETURN ON EQUITY (ROE)
N/A
Electra Therapeutics Inc.
Market Cap
$208.31M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$207.27M
Return on Equity (ROE)
28.68%
TTM Avg
26.59%
3Y Avg
20.62%
5Y Avg
19.74%
Market Cap
$209.91M
Return on Equity (ROE)
39.66%
TTM Avg
4.24%
3Y Avg
-15.88%
5Y Avg
-20.06%
Market Cap
$210.41M
Return on Equity (ROE)
-71.02%
TTM Avg
-15.82%
3Y Avg
-19.73%
5Y Avg
-5.35%
Market Cap
$205.80M
Return on Equity (ROE)
-43.64%
TTM Avg
-68.24%
3Y Avg
-59.30%
5Y Avg
-48.32%
Market Cap
$210.98M
Return on Equity (ROE)
-106.27%
TTM Avg
-100.08%
3Y Avg
-64.49%
5Y Avg
-52.22%
Market Cap
$214.24M
Return on Equity (ROE)
19.38%
TTM Avg
20.63%
3Y Avg
-8.44%
5Y Avg
-40.10%
Market Cap
$214.46M
Return on Equity (ROE)
-36.64%
TTM Avg
6.57%
3Y Avg
27.96%
5Y Avg
27.96%
Market Cap
$215.07M
Return on Equity (ROE)
21.24%
TTM Avg
17.52%
3Y Avg
32.51%
5Y Avg
46.01%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Electra Therapeutics Inc. (ETRA) | $208.31M | N/A | N/A | N/A | N/A |
| Pro-Dex, Inc. (PDEX)vs › | $207.27M | 28.68% | 26.59% | 20.62% | 19.74% |
| Compugen Ltd. (CGEN)vs › | $209.91M | 39.66% | 4.24% | -15.88% | -20.06% |
| Entrada Therapeutics, Inc. (TRDA)vs › | $210.41M | -71.02% | -15.82% | -19.73% | -5.35% |
| Whitehawk Therapeutics Inc (WHWK)vs › | $205.80M | -43.64% | -68.24% | -59.30% | -48.32% |
| Lyell Immunopharma, Inc. (LYEL)vs › | $210.98M | -106.27% | -100.08% | -64.49% | -52.22% |
| Niagen Bioscience Inc (NAGE)vs › | $214.24M | 19.38% | 20.63% | -8.44% | -40.10% |
| Sionna Therapeutics, Inc. (SION)vs › | $214.46M | -36.64% | 6.57% | 27.96% | 27.96% |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $215.07M | 21.24% | 17.52% | 32.51% | 46.01% |
| Alector, Inc. (ALEC)vs › | $200.96M | N/A | -280.12% | -179.90% | -133.80% |
ROE
N/A
ROA
N/A
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
